Beta Bionics (NASDAQ:BBNX) Insider Mark Hopman Sells 775 Shares of Company Stock

Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) insider Mark Hopman sold 775 shares of the business’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $16.22, for a total transaction of $12,570.50. Following the transaction, the insider owned 54,143 shares of the company’s stock, valued at approximately $878,199.46. The trade was a 1.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Mark Hopman also recently made the following trade(s):

  • On Monday, October 26th, Mark Hopman sold 821 shares of Beta Bionics stock. The shares were sold at an average price of $20.00, for a total value of $16,420.00.
  • On Wednesday, October 14th, Mark Hopman sold 775 shares of Beta Bionics stock. The stock was sold at an average price of $17.35, for a total value of $13,446.25.
  • On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The stock was sold at an average price of $18.96, for a total value of $7,015.20.
  • On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The stock was sold at an average price of $20.13, for a total value of $619,581.27.
  • On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The shares were sold at an average price of $18.46, for a total value of $680,620.20.
  • On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total transaction of $101,798.97.

Beta Bionics Stock Down 2.6%

Shares of Beta Bionics stock opened at $14.33 on Thursday. Beta Bionics, Inc. has a 52 week low of $8.80 and a 52 week high of $32.71. The firm’s 50 day moving average is $18.23 and its two-hundred day moving average is $14.87. The firm has a market capitalization of $779.08 million, a P/E ratio of -7.79 and a beta of 3.44.

Beta Bionics (NASDAQ:BBNX – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.01. Beta Bionics had a negative net margin of 65.31% and a negative return on equity of 27.33%. The firm had revenue of $35.51 million for the quarter. As a group, research analysts expect that Beta Bionics, Inc. will post -2.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BBNX. Legal & General Group Plc purchased a new stake in shares of Beta Bionics in the second quarter valued at about $62,000. The Manufacturers Life Insurance Company purchased a new position in shares of Beta Bionics during the second quarter worth about $172,000. 49 Wealth Management LLC acquired a new position in Beta Bionics in the 3rd quarter valued at about $260,000. Ieq Capital LLC acquired a new position in Beta Bionics in the 2nd quarter valued at about $229,000. Finally, Quantbot Technologies LP acquired a new position in shares of Beta Bionics in the second quarter valued at approximately $264,000.

Wall Street Analyst Weigh In

A number of analysts have recently commented on BBNX shares. Barclays began coverage on Beta Bionics in a research report on Tuesday, October 6th. They set an “overweight” rating and a $30.00 target price on the stock. Bank of America raised their price target on Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 15th. Jefferies Financial Group assumed coverage on Beta Bionics in a research report on Monday, October 12th. They set a “buy” rating and a $30.00 price target on the stock. Wall Street Zen cut Beta Bionics from a “hold” rating to a “strong sell” rating in a research note on Saturday, October 31st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Beta Bionics in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.69.

Get Our Latest Research Report on Beta Bionics

Beta Bionics Company Profile

(Get Free Report)

Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings.

Further Reading

Insider Buying and Selling by Quarter for Beta Bionics (NASDAQ:BBNX)

Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.